Abstract
The main inflammatory myopathies within the myositis group include polymyositis, dermatomyositis and inclusion-body myositis (IBM). Although potentially treatable, various practical issues have an impact on the response of these conditions to therapy. The most common reason for therapeutic failure is that the treatment targets the wrong disease, often owing to poor distinction of polymyositis from difficult-to-treat mimics such as sporadic IBM, necrotizing myopathies and inflammatory dystrophies. Evidence from uncontrolled studies suggests that polymyositis and dermatomyositis respond to treatment with prednisone at least to some degree. Empirically, adding an immunosuppressive drug might offer a 'steroid-sparing' effect or perhaps additional benefit. Intravenous immunoglobulin is proven effective as a second-line agent in patients with dermatomyositis and also seems to be effective for those with polymyositis, but offers only minimal and transient benefit to a small proportion of patients with IBM. Small, uncontrolled series suggest other agents such as rituximab or tacrolimus might offer some benefit in disease refractory to the aforementioned therapies, although IBM is resistant to most therapies. Novel agents are emerging as potential treatment options for all forms of myositis. This Review highlights common pitfalls in therapy, discusses emerging new therapies, and provides a practical therapeutic algorithm.
Key Points
-
Correct diagnosis of myositis subtype and monitoring of response to therapy with objective means that document changes in muscle strength are integral to the effective treatment of myositis
-
Immunotherapy for polymyositis and dermatomyositis primarily involves corticosteroids and might incorporate the addition of other immunosuppressive agents
-
Intravenous immunoglobulin might be effective in patients with disease refractory to first-line immunotherapy
-
Inclusion-body myositis has a complex disease mechanism and can be difficult to treat with conventional immunotherapy
-
Various factors in the immunopathogenesis of myositis represent targets for future therapeutic interventions
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dalakas, M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325, 1487–1498 (1991).
Engel, A. G. & Hohlfeld, R. in Myology 3rd edn (eds Engel, A. G. & Franzini-Armstrong, C.) 1321–1366 (McGraw-Hill, New York, 2004).
Mastaglia, F. L. & Phillips, B. A. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum. Dis. Clin. North Am. 28, 723–741 (2002).
Dalakas, M. C. & Hohlfeld, R. Polymyositis and dermatomyositis. Lancet 362, 971–982 (2003).
Dalakas, M. C. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr. Opin. Neurol. 17, 561–567 (2004).
Antiochos, B. B. et al. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J. Rheumatol. 36, 2704–2710 (2009).
Sekul, E. A. & Dalakas, M. C. Inclusion body myositis: new concepts. Semin. Neurol. 13, 256–263 (1993).
Needham, M. & Mastaglia, F. L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 6, 620–631 (2007).
Needham, M. & Mastaglia, F. L. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul. Disord. 18, 6–16 (2008).
Griggs, R. C. et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705–713 (1995).
Greenberg, S. A. et al. Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57, 664–678 (2005).
Askanas, V. & Engel, W. K. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr. Opin. Rheumatol. 10, 530–542 (1998).
Mendel, J. R., Sahenk, Z., Gales, L. & Paul, L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch. Neurol. 48, 1229–1234 (1991).
Dalakas, M. C. Sporadic inclusion body myositis: diagnosis, pathogenesis and therapeutic strategies. Nat. Clin. Prac. Neurol. 2, 437–447 (2006).
Dalakas, M. C. Toxic and drug-induced myopathies. J. Neurol. Neurosurg. Psych. 80, 832–838 (2009).
Karpati, G. & Carpenter, S. Pathology of the inflammatory myopathies. Baillière's Clin. Neurol. 2, 527–556 (1993).
Emslie-Smith, A. M., Arahata, K. & Engel, A. G. Major histocompatibility complex class I antigen expression, immunologicalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum. Pathol. 20, 224–231 (1989).
Karpati, G., Pouliot, Y. & Carpenter, S. Expression of immunoreactive major histocompatability complex products in human skeletal muscles. Ann. Neurol. 23, 64–72 (1988).
Chahin, N. & Engel, A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70, 418–424 (2008).
Blume, G., Pestronk, A., Frank, B. & Johns, D. R. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 120, 39–45 (1997).
Dalakas, M. C. Therapeutic approaches in patients with inflammatory myopathies. Semin. Neurol. 23, 199–206 (2003).
Miller, F. W. et al. Controlled trial of plasma exchange and leukopheresis in patients with polymyositis and dermatomyositis. N. Engl. J. Med. 326, 1380–1384 (1992).
Kissel, J. T., Mendell, J. R. & Rammohan, K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314, 329–334 (1986).
Emslie-Smith, A. M. & Engel, A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27, 343–356 (1990).
Dalakas, M. C. Immunopathogenesis of inflammatory myopathies. Ann. Neurol. 37 (Suppl. 1), S74–S86 (1995).
López de Padilla, C. M. et al. Plasmacytoid dendritic cells in inflamed muscles of patients with juvenile dermatomyositis. Arthritis Rheum. 56, 1658–1668 (2007).
Tews, D. S. & Goebel, H. H. Expression of cell adhesion molecules in inflammatory myopathies. J. Neuroimmunol. 59, 185–194 (1995).
De Bleecker, J. L. & Engel, A. G. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J. Neuropathol. Exp. Neurol. 53, 369–376 (1994).
De Bleecker, J. L., De Paepe, B., Vanwalleghem, I. E. & Schröder, J. M. Differential expression of chemokines in inflammatory myopathies. Neurology 58, 1779–1785 (2002).
Civatte, M. et al. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol. Appl. Neurobiol. 31, 70–79 (2005).
Illa, I. et al. Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies. Am. J. Pathol. 151, 81–88 (1997).
Dalakas, M. C. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat. Clin. Pract. Rheumatol. 2, 219–227 (2006).
Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16, 193–208 (1984).
Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies III Immunoelectron microscopy aspects of cell-mediated muscle fibre injury. Ann. Neurol. 19, 112–125 (1986).
Goebel, N. et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J. Clin. Invest. 97, 2905–2910 (1996).
Bender, A. et al. T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J. Exp. Med. 181, 1863–1868 (1995).
Engel, A. G. & Arahata, K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum. Pathol. 17, 704–721 (1986).
Amemiya, K., Granger, R. P. & Dalakas, M. C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123, 2030–2039 (2000).
Hofbauer, M. et al. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc. Natl Acad. Sci. USA 100, 4090–4095 (2003).
Wiendl, H. et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126, 1026–1035 (2003).
Wiendl, H., Hohlfeld, R. & Kieseier, B. C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 26, 373–380 (2005).
Schmidt, J., Rakocevic, G., Raju, R. & Dalakas, M. C. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 127, 1182–1190 (2004).
Schmidt, J. et al. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 131, 1228–1240 (2008).
Targoff, I. N. Autoantibodies and their significance in myositis. Curr. Rheumatol. Rep. 10, 333–340 (2008).
Dalakas, M. C. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul. Disord. 16, 223–236 (2006).
Bunch, T. W. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 24, 45–48 (1981).
Mastaglia, F. L., Phillips, B. A. & Zilko, P. Treatment of inflammatory myopathies. Muscle Nerve 20, 651–664 (1997).
Dalakas, M. C. Current treatment of the inflammatory myopathies. Curr. Opin. Rheumatol. 6, 595–601 (1994).
Dalakas, M. C. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993–2000 (1993).
Mastaglia, F. L., Phillips, B. A. & Zilko, P. J. Immunoglobulin therapy in inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry 65, 107–110 (1998).
Chérin, P. Current therapy for polymyositis and dermatomyositis [French]. Rev. Med. Interne. 29 (Spec. No. 2), 9–14 (2008).
Dalakas, M. C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367–2375 (2004).
Dalakas, M. C. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 4, 557–567 (2008).
Levine, T. D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52, 601–607 (2005).
Chung, L., Genovese, M. C. & Fiorentino, D. F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch. Dermatol. 143, 763–767 (2007).
Kaposztas, Z., Etheridge, W. B. & Kahan, B. D. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transplant. Proc. 40, 1744–1746 (2008).
Oddis, C. V., Sciurba, F. C., Elmagd, K. A. & Starzl, T. E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353, 1762–1763 (1999).
Shimojima, Y. et al. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin. Rheumatol. 23, 262–265 (2004).
Yamada, A., Ohshima, Y., Omata, N., Yasutomi, M. & Mayumi, M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur. J. Pediatr. 163, 561–562 (2004).
Hohlfeld, R. & Dalakas, M. C. Basic principles of immunotherapy for neurologic diseases. Semin. Neurol. 23, 121–132 (2003).
Wiendl, H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 5, 548–557 (2008).
Hengstman, G. J. et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor necrosis-factor-alpha: preliminary observations. Eur. Neurol. 50, 10–15 (2003).
Labioche, I. et al. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 43, 531–532 (2004).
Hengstman, G. J., van den Hoogen, F. H. & van Engelen, B. G. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur. Neurol. 52, 61–63 (2004).
Dastmalchi, M. et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory polymyositis. Ann. Rheum. Dis. 67, 1670–1677 (2008).
US Food and Drug Administration. FDA public health advisory: updated safety information about Raptiva (efalizumab) [http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm110605.htm] (2009).
Rose, J. W. et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69, 785–789 (2007).
Thomson, B. et al. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J. Rheumatol. 35, 2080–2082 (2008).
O'Connor, P. et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72, 73–79 (2009).
Basta, M. & Dalakas, M. C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729–1735 (1994).
Dalakas, M. C. Interplay between inflammation and degeneration: using inclusion body myositis to study “neuroinflammation”. Ann. Neurol. 64, 1–3 (2008).
Mowzoon, N., Sussman, A. & Bradley, W. G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J. Neurol. Sci. 185, 119–122 (2001).
Dalakas, M. C. et al. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study. Neurology 48, 712–716 (1997).
Walter, M. C. et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247, 22–28 (2000).
Cherin, P. et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58, 326 (2002).
Dalakas, M. C. et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion body myositis. Brain 132, 1536–1544 (2009).
Verma, A., Bradley, W., Adesina, A. M., Sofferman, R. & Pendlebury, W. W. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 14, 470–473 (1991).
Spector, S. A. et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 20, 1242–1248 (1997).
Acknowledgements
Charles P. Vega, University of Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has acted as a consultant for and has received honoraria from Baxter Healthcare, Octapharma and Talecris Biotherapeutics. The Journal Editor J. Buckland and the CME question author C. P. Vega declare no competing interests.
Rights and permissions
About this article
Cite this article
Dalakas, M. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 6, 129–137 (2010). https://doi.org/10.1038/nrrheum.2010.2
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.2
This article is cited by
-
Modulation of mitochondrial activity by sugarcane (Saccharum officinarum L.) top extract and its bioactive polyphenols: a comprehensive transcriptomics analysis in C2C12 myotubes and HepG2 hepatocytes
Natural Products and Bioprospecting (2024)
-
Dermatomyositis Diagnosis and Treatment in the Inpatient Setting
Current Dermatology Reports (2023)
-
Update on Paraneoplastic Neuromuscular Disorders
Current Treatment Options in Neurology (2022)
-
Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study
Rheumatology and Therapy (2021)
-
Physical therapy in adult inflammatory myopathy patients: a systematic review
Clinical Rheumatology (2019)